-
21.
公开(公告)号:US07947835B2
公开(公告)日:2011-05-24
申请号:US11371180
申请日:2006-03-09
申请人: David R. Brittelli , Kevin S. Currie , James W. Darrow , Jeffrey E. Kropf , Seung H. Lee , Steven L. Gallion , Scott A. Mitchell , Douglas A. I. Pippin , Peter A. Blomgren , Douglas Gregory Stafford
发明人: David R. Brittelli , Kevin S. Currie , James W. Darrow , Jeffrey E. Kropf , Seung H. Lee , Steven L. Gallion , Scott A. Mitchell , Douglas A. I. Pippin , Peter A. Blomgren , Douglas Gregory Stafford
IPC分类号: C07D403/12 , C07D403/14 , C07D401/12 , C07D401/14 , A61K31/501 , A61P17/06
CPC分类号: C07D213/74 , C07D241/20 , C07D241/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/04
摘要: At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described.Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
摘要翻译: 本文描述了至少一种选自式2化合物的化学实体及其药学上可接受的盐,溶剂合物,螯合物,非共价复合物,前药及其混合物。 描述了包含本发明的至少一个化学实体的药物组合物以及选自载体佐剂和赋形剂的至少一种药学上可接受的载体。 描述了治疗患有某些对Btk活性和/或B细胞活性的抑制作出反应的某些疾病的患者的方法。 描述了确定样品中Btk的存在的方法。